Adma Biologics, INC Form 4 insider transactions

ADMA Biologics President and CEO Adam S. Grossman reported the exercise of stock options and subsequent sale of shares totaling 21,000 shares of common stock, executed under a pre-arranged Rule 10b5-1 trading plan.

ADMA Biologics Director and 10% Owner Steve Elms reported significant stock transactions, including the exercise of multiple stock options and subsequent sales of common stock, all conducted under a Rule 10b5-1 trading plan.

ADMA Biologics Director Lawrence P. Guiheen sold 20,000 shares of common stock for approximately $419,200, as disclosed in a recent SEC Form 4 filing, with the transaction executed under a Rule 10b5-1 plan.

ADMA Biologics Director Jerrold B. Grossman exercised stock options and simultaneously sold an equal number of shares on June 9, 2025, realizing a substantial profit.

ADMA Biologics Director Lawrence P. Guiheen executed a series of transactions, exercising stock options and subsequently selling the acquired common stock for a significant profit, while maintaining a substantial beneficial ownership.

Adam Grossman, President and CEO of ADMA Biologics, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

ADMA Biologics' CEO, Adam Grossman, exercised stock options and sold shares of common stock on April 15, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Kaitlin Kestenberg-Messina, COO and SVP of Compliance at ADMA Biologics, reports the withholding of shares to cover tax obligations upon the vesting of restricted stock units.

Adam Grossman, CEO of ADMA Biologics, reports the sale of common stock and exercise of options under a pre-arranged trading plan.

Adam Grossman, CEO of ADMA Biologics, reports the withholding of shares to cover tax obligations upon the vesting of restricted stock units.

Kaitlin Kestenberg-Messina, COO and SVP, Compliance of ADMA Biologics, reports the withholding of shares to cover tax obligations upon the vesting of restricted stock units.

Adam Grossman, President and CEO of ADMA Biologics, reports the withholding of shares to cover tax obligations upon the vesting of restricted stock units.

Kaitlin M. Kestenberg-Messina, COO and SVP of Compliance at ADMA Biologics, reports the withholding of shares to cover tax obligations upon vesting of restricted stock units.

CFO Brad L. Tade reports changes in beneficial ownership of ADMA Biologics, Inc. stock due to tax withholding upon vesting of restricted stock units.

Director Young Kwon reports acquisition of ADMA Biologics shares and stock options through restricted stock units and option grants.

Director Eduardo Rene Salas reports the acquisition of restricted stock units and stock options in ADMA Biologics, Inc.

Lawrence P. Guiheen, a director at ADMA Biologics, reports the acquisition of restricted stock units and stock options, along with adjustments to his holdings of common stock.

Director Steve Elms reports acquisition of restricted stock units and stock options in ADMA Biologics, along with details of beneficial ownership.

Director Jerrold B. Grossman reports acquisition of restricted stock units and stock options in ADMA Biologics, along with adjustments to beneficial ownership.

Alison Finger, a director at ADMA Biologics, reported the acquisition of restricted stock units and stock options, as well as the disposal of common stock.

CFO and Treasurer of ADMA Biologics, Brad L. Tade, reports the acquisition of restricted stock units and stock options, increasing his beneficial ownership in the company.

Kaitlin M. Kestenberg-Messina, COO and SVP of Compliance at ADMA Biologics, acquired stock options and restricted stock units (RSUs) on February 19, 2025, according to a Form 4 filing.

Adam Grossman, CEO of ADMA Biologics, reports the acquisition of 252,022 restricted stock units and 376,744 stock options, along with adjustments to existing holdings.

ADMA Biologics' COO, Kaitlin M. Kestenberg-Messina, exercised stock options resulting in a net decrease in her directly held shares after accounting for tax obligations.

ADMA Biologics' COO, Kaitlin M. Kestenberg-Messina, reported a transaction involving the withholding of 1,854 shares to cover taxes upon the vesting of restricted stock units.

ADMA Biologics CEO Adam Grossman reported a transaction involving the withholding of shares to cover taxes upon the vesting of restricted stock units, while also disclosing his beneficial ownership of common stock through various entities.

Eduardo Rene Salas, a director of ADMA Biologics, Inc., was granted stock options on December 30, 2024.

Director Steve Elms of ADMA Biologics exercised stock options and reported changes in his beneficial ownership of company stock.

ADMA Biologics CFO and Treasurer, Brad L. Tade, sold 15,000 shares of common stock at $21.15 per share following the vesting of restricted stock units.

ADMA Biologics CEO Adam Grossman sold 48,967 shares of common stock at an average price of $21.10 following the vesting of restricted stock units.